Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
ABSTRACT Objective This study aims to evaluate the efficacy and safety of PD‐1/PD‐L1 inhibitors in treating small‐cell lung cancer (SCLC) and determine the role of PD‐1 monoclonal antibodies in improving patient outcomes. Methods A retrospective analysis was performed on 37 SCLC patients who receive...
Saved in:
Main Authors: | Qichen Zhang, Xiaojuan Han, Jiayi Liu, Hui Qiao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Cancer Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/cnr2.70081 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01) -
A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer
by: Jie Fu, et al.
Published: (2025-01-01) -
Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer
by: Haowei Wang, et al.
Published: (2025-02-01) -
PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
by: Qingya Song, et al.
Published: (2025-12-01) -
A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors
by: Meijuan Zhai, et al.
Published: (2025-01-01)